Active Ingredient History
Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis. It is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes; Skin and skin structure infections; Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes; Intra-abdominal infections; Septicemia; Bone and joint infections. Orally and parenterally administered clindamycin has been associated with severe colitis, which may end fatally. Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin. Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Bone Diseases, Infectious (approved 1972)
Pelvic Infection (approved 1970)
Reproductive Tract Infections (approved 1972)
Skin and Connective Tissue Diseases (approved 1972)
Skin Diseases, Bacterial (approved 1970)
Abdominal Abscess (Phase 2)
Abortion, Septic (Phase 4)
Abscess (Phase 4)
Amputation (Phase 4)
Anesthesia and Analgesia (Phase 3)
Appendicitis (Phase 4)
Bacterial Infections (Phase 4)
Breast Neoplasms (Phase 3)
Burns (Phase 4)
Candidiasis (Phase 4)
Candidiasis, Vulvovaginal (Phase 3)
Cellulitis (Phase 4)
Chorioretinitis (Phase 3)
Colorectal Neoplasms (Phase 1)
COVID-19 (Phase 2/Phase 3)
Delivery, Obstetric (Phase 4)
Dental Pulp (Phase 4)
Diabetes Mellitus (Phase 3)
Diabetic Foot (Phase 4)
Endometriosis (Phase 1)
Endometrium (Phase 4)
Endophthalmitis (Phase 4)
Exanthema (Phase 2)
Femoral Neck Fractures (Phase 3)
Focal Infection, Dental (Phase 4)
Folliculitis (Phase 4)
Fractures, Bone (Phase 4)
Fractures, Open (Phase 4)
General Surgery (Phase 4)
Glioblastoma (Phase 2)
Head and Neck Neoplasms (Phase 1)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 3)
Hemopneumothorax (Phase 2/Phase 3)
Hernia (Phase 3)
HIV Infections (Phase 3)
Infant, Premature, Diseases (Phase 4)
Infections ()
Inflammation (Phase 4)
Jaw Fractures (Phase 1)
Keratosis, Actinic (Phase 2)
Kidney Calculi (Phase 3)
Malaria (Phase 3)
Nasal Obstruction (Phase 3)
Nasal Surgical Procedures (Phase 3)
Neoplasms (Phase 2)
Obesity (Phase 1)
Obstetrics (Phase 4)
Pain (Phase 3)
Periodontal Pocket (Phase 3)
Periodontitis (Phase 3)
Pneumonia, Pneumocystis (Phase 4)
Pneumothorax (Phase 2/Phase 3)
Postpartum Hemorrhage (Phase 4)
Postpartum Period (Phase 4)
Prediabetic State (Phase 2)
Pregnancy (Phase 4)
Premature Birth (Phase 4)
Prosthesis-Related Infections (Phase 2)
Rosacea (Phase 2/Phase 3)
Salivary Ducts (Phase 4)
Sick Sinus Syndrome (Phase 3)
Signs and Symptoms (Phase 3)
Skin Diseases (Phase 3)
Skin Diseases, Bacterial (Phase 3)
Skin Diseases, Infectious (Phase 3)
Staphylococcal Infections (Phase 4)
Surgical Wound Infection (Phase 3)
Syncope (Phase 3)
Traumatology (Phase 4)
Urinary Bladder Neoplasms (Phase 4)
Urinary Tract Infections (Phase 4)
Vagina (Phase 3)
Vaginal Diseases (Phase 4)
Vaginitis (Phase 3)
Vaginosis, Bacterial (Phase 4)
Vulvovaginitis (Phase 3)
Wound Infection (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
